Biogen Inc.
—- Market cap
- $31.88B
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $31.88B · View financials
Snapshot Sep 11, 2026, 11:24 AM ET
FY 2025 · Mkt cap
Decision snapshot: BIIB stock price near parity vs LH $215.94 current versus $257.26 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LH's multiple
Implied fair value · at BIIB's multiple
Snapshot Sep 11, 2026, 11:24 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 82% equity / 18% debt · EV / Revenue 2.14x · EV proxy / EBITDA proxy 14.46x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BIOGEN INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
LABCORP HOLDINGS INC. · implied price per share
Bear
$113.84
Base
$138.62
Bull
$182.73
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
BIIB vs PFE
JOHNSON & JOHNSON
BIIB vs JNJ
AMGEN INC
BIIB vs AMGN
ELI LILLY & Co
BIIB vs LLY
Natera, Inc.
BIIB vs NTRA
ILLUMINA, INC.
BIIB vs ILMN
THERMO FISHER SCIENTIFIC INC.
BIIB vs TMO
DANAHER CORP /DE/
BIIB vs DHR
QUEST DIAGNOSTICS INC
BIIB vs DGX
WEST PHARMACEUTICAL SERVICES INC
BIIB vs WST
BAXTER INTERNATIONAL INC
BIIB vs BAX
MCKESSON CORP
BIIB vs MCK
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BIIB can sustain its high margins while closing the growth gap with LH, then BIIB looks worth owning on a relative value basis because it trades at a lower P/E despite stronger profitability and lower leverage.
BIIB’s implied price of $268.21 sits 29.0% above the current price of $207.94, suggesting meaningful upside versus LH-based P/E framework. However, the stock already trades above the lower end of both LH-implied range and the DCF range, so the valuation gap is supportive but not extreme.
Supporting Metrics